血小板靶向高活性FIX基因治疗用于存在抗FIX免疫的血友病B小鼠
该研究在FIXnull小鼠中采用慢病毒介导的血小板特异性高活性FIX-Padua(2bCoF9R338L)基因治疗,使血小板FIX活性达70%–122%(35.08–60.77 mU/10^8血小板)。在高度免疫的受体中仍实现持续表达,抗FIX抗体滴度随时间下降并建立免疫耐受,出血表型被完全纠正。
要点
- 2bCoF9R338L基因治疗使FIXnull小鼠血小板FIX活性达70%–122%。
- 高度免疫受体中仍获持续表达,活性为18.00±9.11和9.36±12.23 mU/10^8血小板。
- 联合硼替佐米预处理有助于清除抗FIX抗体,出血表型完全纠正。
核心结论
- 2bCoF9R338L基因治疗可能适用于所有血友病B患者,包括存在抑制物的患者。
研究设计与样本
- 在FIXnull小鼠中开展慢病毒介导的血小板特异性FIX基因治疗研究,比较2bCoF9R338L与既往2bF9盒。
主要发现
- 2bCoF9R338L转导的FIXnull小鼠全血FIX活性达70%–122%(35.08–60.77 mU/10^8血小板)。
- 高度免疫受体经11 Gy和6.6 Gy预处理后血小板FIX活性分别为18.00±9.11和9.36±12.23 mU/10^8血小板。
- 抗FIX抗体滴度随时间下降,基因治疗后建立免疫耐受。
- 硼替佐米加入预处理有助于清除抗FIX抗体。
- 抑制物降至检测不到后,尾出血试验和针诱导膝关节损伤模型中出血表型完全纠正,ROTEM和TGA进一步证实止血疗效。
临床怎么用
- 对于存在抗FIX免疫的血友病B患者,血小板靶向高活性FIX基因治疗可能实现持续止血并诱导免疫耐受。
- 硼替佐米预处理可能作为清除抗FIX抗体的辅助策略。
局限性
- 研究仅在小鼠模型中进行,尚未在人体验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Gene therapy may lead to a cure for hemophilia B (HB) if it is successful. Data from clinical trials using adeno-associated virus (AAV)-mediated liver-targeted FIX gene therapy are very encouraging. However, this protocol can be applied only to adults who do not have liver disease or anti-AAV antibodies, which occur in 30% to 50% of individuals. Thus, developing a protocol that can be applied to all HB patients is desired. Our previous studies have demonstrated that lentivirus-mediated platelet-specific FIX (2bF9) gene therapy can rescue bleeding diathesis and induce immune tolerance in FIXnull mice, but FIX expression was only ∼2% to 3% in whole blood. To improve the efficacy, we used a codon-optimized hyperfunctional FIX-Padua (2bCoF9R338L) to replace the 2bF9 cassette, resulting in 70% to 122% (35.08-60.77 mU/108 platelets) activity levels in 2bCoF9R338L-transduced FIXnull mice. Importantly, sustained hyperfunctional platelet-FIX expression was achieved in all 2bCoF9R338L-transduced highly immunized recipients with activity levels of 18.00 ± 9.11 and 9.36 ± 12.23 mU/108 platelets in the groups treated with 11 Gy and 6.6 Gy, respectively. The anti-FIX antibody titers declined with time, and immune tolerance was established after 2bCoF9R338L gene therapy. We found that incorporating the proteasome inhibitor bortezomib into preconditioning can help eliminate anti-FIX antibodies. The bleeding phenotype in 2bCoF9R338L-transduced recipients was completely rescued in a tail bleeding test and a needle-induced knee joint injury model once inhibitors dropped to undetectable. The hemostatic efficacy in 2bCoF9R338L-transduced recipients was further confirmed by ROTEM and thrombin generation assay (TGA). Together, our studies suggest that 2bCoF9R338L gene therapy can be a promising protocol for all HB patients, including patients with inhibitors.
引用
- Schroeder JA, Chen J, Chen Y, et al. Platelet-targeted hyperfunctional FIX gene therapy for hemophilia B mice even with preexisting anti-FIX immunity. Blood Adv. 2021. PMID: 33646304. doi:10.1182/bloodadvances.2020004071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。